Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(20 sites)
China
Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality Fujian Cancer Hospital, Fuzhou, Fujian The First Affiliated Hospital of Xiamen University, Xiamen, Fujian Zhangzhou Municiple Hospital of Fujian Province, Zhangzhou, Fujian Dongguan People's Hospital, Dongguan, Guangdong